Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Company

ANI Pharmaceuticals

Tracked across 3 events · 20 articles · First seen Apr 20, 2026 · Last active Sep 23, 2026

Sentiment
25
Attention
2
Events
3
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
1 60
Business
Impact: ANI Pharmaceuticals is the company whose CFO sold shares; it reported strong Q1 results and raised guidance, indicating positive business momentum.
Jul 09, 2026 · 6 articles
2 25
Regulatory
ANI Pharmaceuticals received final approval from the U.S. United States — Food and Drug Administration for its Abbreviated New Drug Application for Everolimus Tablets for Oral Suspension in 2mg, 3mg and 5mg strengths. The product…
Impact: ANI Pharmaceuticals is the central beneficiary of the event, receiving FDA approval for generic Everolimus Tablets for Oral Suspension and expanding its generics portfolio. The approval supports its goal of launching at least 15 new generics in 2026 and adds a product with about $123 million in annual U.S. sales.
Sep 23, 2026 · 7 articles
2 -10
Business
Impact: ANI Pharmaceuticals lost its post-trial motion in the Delaware court, with the ruling upholding the jury verdict against its challenges. This resolves a legal dispute in CG Oncology's favor.
Aug 06, 2026 · 7 articles
ERGEN INTELLIGENCE
Track ANI Pharmaceuticals live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.